Prognostic significance of biologic markers in node-negative breast cancer patients: A prospective study

Breast Cancer Research and Treatment

Volumn 63, Issue 3, 2000, Pages 181-192

  Volpi, A ^a   De Paola, F ^a   Nanni, O ^a   Granato, A M ^a   Bajorko, P ^a   Becciolini, A ^a   Scarpi, E ^a   Riccobon, A ^a   Balzi, M ^a   Amadori, D ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Biologic markers; Node negative breast cancer; Prognosis

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P27;

ADULT; ARTICLE; BREAST CANCER; DNA SYNTHESIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL DIVISION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; THYMIDINE;

EID: 0033731947     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006464426977     Document Type: Article

References (73)

1. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13
2. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer
3. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer
4. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer
5. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
6. A licence to kill
7. Caspases: Intracellular signaling by proteolysis
8. What is the evidence that tumors are angiogenesis dependent?
9. Angiogenesis and breast cancer
10. Overexpression of cyclin D1 enhances gene amplification
11. Amplification of a novel v-erbB related gene in a human mammary carcinoma
12. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
13. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors
14. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
15. The type 1 growth factor receptor family: New ligands and receptors and their role in breast cancer
16. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
17. The p53 tumor suppressor gene
18. Implication of the p53 tumor suppressor gene in clinical oncology
19. p53 As an independent prognostic marker in node-negative breast cancers
20. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers
21. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer
22. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy
23. 3H-thymidine labeling index as a prognostic indicator in node-positive breast cancer
24. The SICCAB Group for quality control of cell kinetic determination: Feasibility and reproducibility of the 3H-TdR labeling index in breast cancer
25. Characterization of laboratory working standards for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation of breast cancer biopsies
26. Nonparametric estimation for incomplete observation
27. Regression models and life tables
28. Cell proliferation in relation to clinical features and relapse in breast cancers
29. Cell proliferation in 3800 node-negative breast cancers: Consistency over time of biological and clinical information provided by 3H-thymidine labelling index
30. The long term prognostic significance of the thymidine labeling index in breast cancer
31. Prediction of early course of breast carcinoma by thymidine labeling
32. The DNA labeling index: A prognostic factor in node-negative breast cancer
33. Proliferative index of breast cancer by thymidine labeling index: Prognostic power independent of stage, estrogen and progesteron receptors
34. Cell kinetics as a prognostic indicator in node-negative breast cancer
35. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer
36. Fattori prognostici nel carcinoma della mammella operabile N-: Attivita proliferativa e caratteristiche clinico-patologiche
37. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer
38. Cell kinetics as a prognostic marker in node-negative breast cancer
39. Biologic and clinico-pathologic factors as indicators of specific relapse types in node-negative breast cancer
40. ERBB 2 oncogene in human breast cancer and its clinical significance
41. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor-long term survival in breast cancer
42. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients
43. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors
44. Combined overexpression of cerbB-2 protein and epidermal growth factor receptor (EGR-R) could be predictive of early and long-term outcome in human breast cancer: A pilot study
45. The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients
46. The relationship between cerbB-2 expression, S-phase fraction and prognosis in breast cancer
47. In situ distrubution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-β-subunit
48. c-erbB-2 oncoprotein expression in primary and advanced breast cancer
49. Prognostic value of c-erbB-2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol
50. Relationship between c-erbB-2 immunoreactivity and thymidine labeling index in breast carcinoma in situ
51. High cell kinetics is associated with amplification of the int-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers
52. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
53. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up
54. Prognostic importance of c-erbB-2 expression in breast cancer
55. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
56. c-erbB-2 expression and response to adjuvant therapy in women with node-posivite early breast cancer
57. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
58. p185 c-erbB-2 signalling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drag-induced DNA repair
59. HER2 overexpression and paclitaxel sensitivity in breast cancer; therapeutic implications
60. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
61. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
62. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas
63. 1 protein: Prognostic implications in primary breast cancer
64. 1 and apoptosis in human breast cancer
65. 1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients
66. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients
67. Tritiated thymidine labeling index and response in human breast cancer
68. Tumor cell kinetics and course of node-positive (N+) breast cancer
69. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer
70. Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer
71. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study